Philip Bierman is an Oncology physician affiliated with University of Nebraska at Omaha. OpenAlex indexes 304 publications with 10,647 citations (h-index 61); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
988102 Nebraska Medical Ctr
Omaha, NE 681988102
Telephone
402-559-9800Registry record last updated 15 Jun 2011.
Clinical trials
- Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
Sponsor: Bradmer Pharmaceuticals Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Imbruvica100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement
American Journal of Transplantation
2020 - Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
Journal of Clinical Oncology
2020 - Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2020 - Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement
American Journal of Transplantation
2020 - NCCN Guidelines Insights: Antiemesis, Version 2.2017
Journal of the National Comprehensive Cancer Network
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Stephen Rennard, MD
University of Nebraska at Omaha
Rudy Lackner, MD
University of Nebraska at Omaha
Iraklis Pipinos, MD
University of Nebraska at Omaha
William Roccaforte, MD
University of Nebraska at Omaha
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”